Eli Lilly

Eli Lilly and Company (LLY) today September 17, announced positive topline results from ACHIEVE-3, Phase 3 clinical trial evaluating the safety and efficacy of orforglipron compared to oral semaglutide, administered according to approved label instructions in 1,698 adults with type 2 diabetes inadequately controlled with metformin.

The 52-week trial compared orforglipron (12 mg and 36 mg) to oral . . .